Company news
Hubei Jumpcan Pharmaceutical Co., Ltd Class A (SSE:600566) news
Hubei Jumpcan Pharmaceutical Co., Ltd Class A news releases on 6ix. Latest, Sep 25, 2026: "Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement…
Press releases & updates
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Implementation of Self-exercise for the Second Exercise Period of Stock Options of the Initial Grant under the 2022 Restricted Share and Stock Option Incentive Plan
September 24, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Lifting of Restrictions and Listing of Restricted Shares of the Initial Grant for the Second Lifting Period under the 2022 Restricted Share and Stock Option Incentive Plan
September 21, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Completion of Cancellation of Certain Stock Options under the 2022 Restricted Share and Stock Option Incentive Plan
September 17, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Satisfaction of Conditions for Lifting of Restrictions for the Second Lifting Period and Exercise Conditions for the Second Exercise Period of the Initial Grant under the 2022 Restricted Share and Stock Option Incentive Plan
September 8, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Results of Shareholding Reduction by Certain Directors
September 1, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026
August 28, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Implementation of Repurchase and Cancellation of Certain Shares under the Employee Stock Ownership Plan
August 25, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate by Subsidiary
August 9, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Implementation of Repurchase and Cancellation of Certain Restricted Shares under the 2022 Restricted Share and Stock Option Incentive Plan
August 7, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on the Shareholding Reduction Plan of Certain Directors and Senior Management
August 6, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Indicative Announcement on Restricted Exercise Period for the Initial Grant of Stock Options under the 2022 Restricted Share and Stock Option Incentive Plan
August 5, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
July 31, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Completion of the Cancellation of Certain Share Options under the 2022 Restricted Share and Share Option Incentive Plan
July 24, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Inclusion of Key Products in the National Essential Medicines List
July 9, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Attending the 2026 Collective Reception Day for Investors of Listed Companies in Hubei Jurisdiction and 2025 Annual Performance Briefing
July 3, 2026
"Hubei Jumpcan Pharmaceutical Co., Ltd."Announcement on Self-exercise Results and Changes in Share Capital of 2022 Restricted Stock and Stock Option Incentive Plan in Q2 2026
July 1, 2026
Announcement on Adjustment of the Exercise Price of Stock Options of Initial Grant under the 2022 Restricted Stock and Stock Option Incentive Plan
June 23, 2026
Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
June 11, 2026
Announcement on the Obtaining of the Drug Registration Certificate for the New Indication of the Collaborative Product Masiloxavir Tablets
June 8, 2026
Announcement on Completion of Non-trading Transfer under the 2026 Employee Stock Ownership Plan
June 1, 2026
Indicative Announcement on Restricted Exercise Period for the Stock Options Initially Granted in 2022 Restricted Stock and Stock Option Incentive Plan
May 27, 2026
Indicative Announcement on Expiration of the 2nd Lock-up Period of 2024 Employee Stock Ownership Plan
May 22, 2026
Announcement on Approval of Pudilan Xiaoyan Oral Liquid as a National Protected Traditional Chinese Medicine Variety
May 17, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 15, 2026
Indicative Announcement on Convening the 2025 Annual General Meeting
May 8, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
May 7, 2026
Announcement on Receipt of Drug Registration Application Acceptance Notice
April 27, 2026
Announcement on Resolutions of the 20th Meeting of the 10th Board of Directors
April 23, 2026
Announcement on Self-exercise Results and Changes in Share Capital of 2022 Restricted Stock and Stock Option Incentive Plan in Q1 2026
April 1, 2026
Announcement on Progress in Wholly-owned Subsidiary Using Idle Raised Funds for Cash Management
March 6, 2026
Indicative Announcement on Expiration of Term of Certain Independent Directors
February 27, 2026
Announcement on the Voluntary Disclosure Regarding the Execution of an Exclusive Commercialization Rights Agreement by a Wholly-owned Subsidiary
February 26, 2026
Announcement on the Voluntary Disclosure Regarding the Execution of an Exclusive Commercialization Cooperation Agreement by a Wholly-owned Subsidiary
February 2, 2026
Announcement on Initially Repurchasing Shares through Call Auction
January 13, 2026
Announcement on Self-exercise Results and Changes in Share Capital of 2022 Restricted Stock and Stock Option Incentive Plan in Q4 2025
January 5, 2026
Announcement on Shareholding of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Limit Concerning Shares Repurchase
December 1, 2025
Announcement on Resolutions of the 19th Meeting of the 10th Board of Directors
November 24, 2025
Announcement on Implementation of Repurchase and Cancellation of Partial Restricted Stocks under 2022 Restricted Stock and Stock Option Incentive Plan
November 21, 2025
湖北济川药业股份有限公司关于全资子公司开立募集资金现金管理专用结算账户并利用闲置募集资金进行现金管理的进展公告
November 18, 2025
Announcement on Progress in Wholly-owned Subsidiaries Opening Special Settlement Account for Cash Management of Raised Funds and Using Idle Raised Funds for Cash Management
November 11, 2025
Report for Q3 2025
October 27, 2025
Announcement on Implementation of Independent Exercise in the 1st Exercise Period of Initially Granted Stock Options in 2022 Restricted Stock and Stock Option Incentive Plan
October 9, 2025
Announcement on Lifting Trading Restrictions and Listing of the 1st Trade Restriction Release Period of Initially Granted Restricted Stock under the 2022 Restricted Stock and Stock Option Incentive Plan
September 24, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 23, 2025
Announcement on Resignation of Non-independent Director and Election of Employee Representative Director
September 19, 2025
Announcement on Obtaining Drug Registration Certificate by Subsidiary
September 16, 2025
Announcement on the Release of Pledge for Shares Held by the Controlling Shareholder
September 15, 2025
Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025
September 12, 2025
Indicative Announcement on the Use of Self-exercise for the 1st Exercise Period of Stock Options of Initial Grant under the 2022 Restricted Stock and Stock Option Incentive Plan
September 9, 2025
Announcement on Progress in Wholly-Owned Subsidiary’s Utilization of Idle Raised Capital for Cash Management, Redemption at Maturity, and Continued Cash Management
September 3, 2025